NeoPhore Ltd. collaboration to continue exploring anti-tumour DNA mismatch repair inhibitors

NeoPhore Ltd. have entered a 3-year collaboration with leading cancer centre in New York, USA. 

Based in Cambridge, UK, NeoPhore prioritises small molecule drug and therapeutic development for the treatment of cancers through immune system stimulation. Neoantigens are a tumor-specific antigen generated by mutations within the tumour cell itself. These neoantigens can be exploited to overcome the natural mechanisms of traditional cancers. NeoPhore hopes to build a therapeutic pipeline targeting novel proteins across DNA MMR pathways, with MMR modulators that can alter the genotype of tumour cells to increase mutational burden, higher neoantigen presence and tumour immunogenicity, eliciting an anti-tumour immune response. 

Matthew Baker, CEO of Neophore, commented: “Collaborating with such prominent leaders in the field of applied cancer genetics is a great privilege. NeoPhore’s therapeutic concept aims to induce neoantigen creation and cancer immunity using small-molecule inhibitors of mismatch repair, particularly in combination with other immunotherapy approaches. We look forward to the outcome of this collaboration which will ultimately advance our goal to develop next-generation immuno-oncology therapeutics.” 

Source: NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist's Lab at Major US Cancer Center (prnewswire.com)